Humacyte Inc
About Company
Humacyte Inc (Nasdaq: HUMA) is a biotechnology company developing a platform to create universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems. Their focus is on improving patient lives and transforming medical practices. The company manufactures acellular tissues to treat various diseases, injuries, and chronic conditions. Their primary product is a portfolio of Acellular Tissue Engineered Vessels (ATEVs), currently approved for vascular trauma repair and in late-stage clinical trials for applications like hemodialysis AV access and peripheral arterial disease. Preclinical development is also underway for coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes treatment, and other novel cell and tissue applications. Their 6mm ATEV for hemodialysis AV access and urgent arterial repair received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
